Literature DB >> 2390486

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

C Meijer1, N H Mulder, G A Hospers, D R Uges, E G de Vries.   

Abstract

The role of glutathione (GSH) in resistance to cisplatin (CDDP) was studied in a human small cell lung carcinoma cell line (GLC4) and a CDDP-resistant subline (GLC4-CDDP). In addition to studying the steady state of GSH, the kinetics of this defence system were also studied via the monitoring of the GSH status of the cells under continuous pressure of CDDP. GLC4-CDDP maintained its elevated GSH level whereas GLC4 (under pressure of CDDP) quickly synthesised GSH to about twice its initial level, corresponding with 80% of the GSH level of GLC4-CDDP. D,L-buthionine-S,R-sulphoximine (BSO) was used to analyse the role of GSH in resistance to CDDP. Pretreatment with BSO (48 h, 50 microM, GSH not detectable) increased the CDDP-induced cytotoxicity 2.8-fold in GLC4-CDDP and 1.7-fold in GLC4. In GLC4 no changes in the amount of platinum (Pt) bound to DNA could be observed after GSH depletion. Changes in formation of interstrand cross-links or the main Pt-containing intrastrand cross-link in digested DNA, the Pt-GG adduct, were also not observed. In GSH depleted GLC4-CDDP cells, an increase in the amount of Pt bound to DNA and in the Pt-GG adduct was observed. Pretreatment with BSO substantially reduced the repair of Pt bound to DNA in both cell lines. We conclude that an increased GSH level and GSH synthesis capacity were demonstrated in CDDP resistant cells. The observations after BSO treatment suggest two roles for GSH in CDDP resistance, namely that of a cytosolic elimination resulting in less DNA platination and a nuclear effect on the formation and repair of DNA platinum adducts.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390486      PMCID: PMC1971741          DOI: 10.1038/bjc.1990.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.

Authors:  P Bedford; A M Fichtinger-Schepman; S A Shellard; M C Walker; J R Masters; B T Hill
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

2.  Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

Authors:  A J Kraker; C W Moore
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.

Authors:  J Hansson; M Edgren; H Ehrsson; U Ringborg; B Nilsson
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

4.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

Authors:  A Eastman; N Schulte
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

5.  Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues.

Authors:  F Tietze
Journal:  Anal Biochem       Date:  1969-03       Impact factor: 3.365

6.  Effects of dimethyl sulfoxide and thiourea upon intercalator-induced DNA single-strand breaks in mouse leukemia (L1210) cells.

Authors:  Y Pommier; L A Zwelling; M R Mattern; L C Erickson; D Kerrigan; R Schwartz; K W Kohn
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

Review 7.  Glutathione metabolism as a determinant of therapeutic efficacy: a review.

Authors:  B A Arrick; C F Nathan
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

8.  Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

Authors:  W R Waud
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

9.  Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.

Authors:  J A Green; D T Vistica; R C Young; T C Hamilton; A M Rogan; R F Ozols
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

10.  Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells.

Authors:  K Micetich; L A Zwelling; K W Kohn
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

View more
  21 in total

Review 1.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.

Authors:  E Fokkema; E G E De Vries; H J M Groen; C Meijer; W Timens
Journal:  Virchows Arch       Date:  2003-02-21       Impact factor: 4.064

3.  Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels.

Authors:  M R Müller; K A Wright; P R Twentyman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

Authors:  W T van der Graaf; N H Mulder; C Meijer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 5.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

6.  Transient cisplatin-resistant murine fibrosarcoma cell characterized by increased metallothionein content.

Authors:  H Eichholtz-Wirth; R Born; G Reidel; B Hietel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines.

Authors:  Alexander J Neuwelt; Y Jeffrey Wu; Narcyz Knap; Marcin Losin; Edward A Neuwelt; Michael A Pagel; Steven Warmann; Joerg Fuchs; Piotr Czauderna; Michal Wozniak
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

9.  Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.

Authors:  T Sasada; S Iwata; N Sato; Y Kitaoka; K Hirota; K Nakamura; A Nishiyama; Y Taniguchi; A Takabayashi; J Yodoi
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.